DFDavid E. Fleischer

David E. Fleischer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David E. Fleischer has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influence of Small Bowel Capsule Endoscopy on Clinical Outcome

    by Lucia C. Fry, Carolina Olano, Friedrich Hagenmüller, Jörg G. Albert, David E. Fleischer

  • Open Access

    Multicenter study on the diagnostic performance of multiframe volumetric laser endomicroscopy targets for Barrett’s esophagus neoplasia with histopathology correlation

    by M R Struyvenberg, A J de Groof, A Kahn, B L A M Weusten, D E Fleischer, E K Ganguly, V J A Konda, C J Lightdale, D K Pleskow, A Sethi, et al.

    Volumetric laser endomicroscopy (VLE) has been shown to improve detection of early neoplasia in Barrett’s esophagus (BE). However, diagnostic performance using histopathology-correlated VLE regions of interest (ROIs) has not been adequately studied. We evaluated the diagnostic accuracy of VLE assessors for identification of early BE neoplasia in histopathology-correlated VLE ROIs. In total, 191 ROIs (120 nondysplastic and 71 neoplastic) from 50 BE patients were evaluated in a random order using a web-based module. All ROIs contained histopathology correlations enabled by VLE laser marking. Assessors were blinded to endoscopic BE images and histology. ROIs were first scored as nondysplastic or neoplastic. Level of confidence was assigned to the predicted diagnosis. Outcome measures were: (i) diagnostic performance of VLE assessors for identification of BE neoplasia in all VLE ROIs, defined as accuracy, sensitivity, and specificity; (ii) diagnostic performance of VLE assessors for only high level of confidence predictions; and (iii) interobserver agreement. Accuracy, sensitivity, and specificity for BE neoplasia identification were 79% (confidence interval [CI], 75–83), 75% (CI, 71–79), and 81% (CI, 76–86), respectively. When neoplasia was identified with a high level of confidence, accuracy, sensitivity, and specificity were 88%, 83%, and 90%, respectively. The overall strength of interobserver agreement was fair (k = 0.29). VLE assessors can identify BE neoplasia with reasonable diagnostic accuracy in histopathology-correlated VLE ROIs, and accuracy is enhanced when BE neoplasia is identified with high level of confidence. Future work should focus on renewed VLE image reviewing criteria and real-time automatic assessment of VLE scans.


  • Intestinal metaplasia of the gastric cardia: findings in patients with versus without Barrett’s esophagus

    by Hassan A. Siddiki, Dora M. Lam-Himlin, Allon Kahn, M. Veronica Bandres, George E. Burdick, Michael D. Crowell, Rahul Pannala, Francisco C. Ramirez, Marcelo F. Vela, David E. Fleischer


  • The Republic of Malta and endoscopic eradication therapy for Barrett’s esophagus

    by David E. Fleischer

    Malta is a southern European island country in the Mediterranean. It has been inhabited since 5900 BC. The population is 460 000 and the gross domestic product (GDP) in 2017 was 19.7 billion dollars. It is one of the 28 countries in the European Union (EU), which has 511 million member citizens and a GDP of 20 trillion dollars. And, although you cannot make predictions about what the EU will look like in 10 years without including a study of Malta, it is not the main determinant of the future of the EU. It is a valuable but small piece of the puzzle. Radiofrequency ablation (RFA) for the treatment of low grade dysplasia (LGD) in patients with Barrett’s esophagus (BE) has been shown to safely eradicate intestinal metaplasia and dysplasia in Barrett’s patients with LGD and to reduce the rates of progression from LGD to high grade dysplasia (HGD) and cancer in the short term. Because of this, it has been a valuable option for managing patients with LGD. However, it is unlikely that in 2030 RFA (or any other endoscopic eradication therapy [EET]) will be a main determinant in the management and outcome of patients with Barrett’s. It is likely to be a small piece of the puzzle. All commentary underlies the opinion that the only reason that Barrett’s is important is because it is the main precursor of adenocarcinoma of the esophagus. The investigation of BE provides a template to understand the development of esophageal adenocarcinoma. This editorial comment on the paper of Pandey et al. entitled “Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett’s esophagus” [1] reviews the limitations of the studies that were included in the meta-analysis and outlines future strategies to prevent esophageal adenocarcinoma and to manage BE. “...in addition to focusing on patients with known Barrett’s, attention must be turned to the “pre-Barrett’s” crowd, both patients with esophageal reflux symptoms and those who are asymptomatic.” The systematic review and meta-analysis by Pandey et al. is a valuable addition to the literature. It culls the 423 articles on this subject, which were identified in databases, down to eight articles: two randomized controlled trials (RCTs) and six observational cohort studies with a mean follow-up of 20 months [2] [3] [4] [5] [6] [7] [8] [9]. Of the eight studies, six evaluated complete eradication of intestinal metaplasia (CE-IM) and of dysphagia (CE-D). The range of CE-IM was 77 % – 93 %, with an overall pooled rate of 88.17 %. The range of CE-D was 83 % – 98 %, with an overall pooled rate 96.69 %. Three of the eight studies compared progression to HGD or cancer, and patients who had RFA were less likely to progress (odds ratio 0.07, 95 % confidence interval 0.02 – 0.22). Recurrence rates were evaluated in five of the eight studies, with a range of recurrence of intestinal metaplasia of 2.8 % – 25 % and a range of recurrence of dysplasia from 0 – 16 %. Adverse events were listed in five of the eight studies and were very acceptable. The authors concluded that RFA safely eradicates intestinal metaplasia and dysplasia, and reduces the rates of progression from LGD to HGD or cancer in the short term. Data from the studies reviewed are the foundation upon which the most recent American College of Gastroenterology guidelines [10] and the European Society of Gastrointestinal Endoscopy (ESGE) position statement [11] are based. Although the systematic review is based on the best data available, the reader should consider the following. First, these results were obtained in expert medical centers by expert endoscopists. Do these results apply to the practicing community? Second, in one of the studies [9], it was not possible to achieve CE-IM in one of five patients, and in another study [3], 17 % did not achieve CE-D. Third, in the two RCTs, how is it possible that 22 % of patients in the control group in one study [6] and 28 % of the control group in another study [7] had “eradication” of dysplasia? Does that mean that LGD (even after confirmation by two expert pathologists) can regress or does it mean that there is sampling error? The accuracy of endoscopic biopsies for defining histopathology, whether for initial screening, surveillance or post EET, has always been regarded as imperfect. With long-segment BE, less than 5 % of the area is sampled, which may lead to misdiagnosis. Would post-EET surveillance be better carried out with wide-area transepithelial sampling, as a recent RCT [12] suggested? The aforementioned guidelines [10] [11] recommend the use of high definition, high resolution endoscopes. These guidelines also emphasize that resection techniques rather than RFA and other thermal therapies be used for nodular lesions. In three of the referenced eight studies, a combination of endoscopic mucosal resection (EMR) and RFA was used. Fourth, are buried glands/subsquamous intestinal metaplasia (SSIM) important? The study by Shaheen et al. [7] suggests not. A recent study in treatment-naïve patients found SSIM in 40 % of patients with extension proximal to the squamocolumnar junction in 20 % of patients [13]. Although SSIM was common, the authors emphasize the low neoplasia potential of SSIM. Now that the subsquamous anatomy can be better assessed with volumetric laser endomicroscopy (VLE), should this be the standard of care after EET [14]; will newer technologies coupled with VLE, such as optical coherence angiography, provide even more information; and because there is interobserver variation with VLE, will the new artificial intelligence technology lead not only to standardization of interpretation but also to increased diagnostic accuracy? Another point to consider is the fact that the meta-analysis evaluates RFA for treatment of LGD, but is RFA even the best EET? It is not...

  • Tu1144 Dysplastic Burden in Barrett's Esophagus With Low-Grade Dysplasia Is Associated With Progression to High-grade Dysplasia or Adenocarcinoma

    by Allon Kahn, Jonathan K. Callaway, Mohanad Al-Qaisi, David E. Fleischer, George E. Burdick, Rahul Pannala, Dora Lam-Himlin, Marcelo F. Vela, Francisco C. Ramirez


  • Tu1145 Prevalence of Concomitant Dysplasia in Barrett’s Esophagus and Esophageal Adenocarcinoma

    by Allon Kahn, Jonathan K. Callaway, Mohanad Al-Qaisi, David E. Fleischer, George E. Burdick, Rahul Pannala, Dora Lam-Himlin, Marcelo F. Vela, Francisco C. Ramirez

  • Su1079 Esophageal Motility Disorders, Response to Multiple Rapid Swallows, and Bolus Transit Abnormalities in Patients With Non-Obstructive Dysphagia

    by Laya Nasrollah, Mohanad Al-Qaisi, Michael Crowell, George E. Burdick, David E. Fleischer, Francisco C. Ramirez, Marcelo F. Vela

  • Su1089 Esophagogastric Junction Outflow Obstruction Disorders. A Clinical and Manometric Comparison of EGJ Outflow Obstruction (EJGOO) and Achalasia

    by Hassan A. Siddiki, Mohanad Al-Qaisi, Michael Crowell, George E. Burdick, Francisco C. Ramirez, David E. Fleischer, Marcelo F. Vela

  • Influence of Small Bowel Capsule Endoscopy on Clinical Outcome

    by Lucia C. Fry, Friedrich Hagenmüller, Jörg G. Albert, David E. Fleischer

  • Fields of Application

    by Mark E. McAlindon, Friedrich Hagenmüller, David E. Fleischer